Improving the availability of innovative medicines in Latin America is a key priority for the pharmaceutical industry, policymakers, and patients.
That was the conclusion of the first study on access to innovative therapies, which was launched by Fifarma, the trade group for Latin America's pharmaceutical industry.
The study analyzed the availability and time taken to access innovative medicines for orphan diseases and oncologic illness in eight Latin American countries including Brazil, Chile, Mexico, Peru, Argentina and Costa Rica.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze